Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features

Journal of International Medical Research

Volumn 37, Issue 2, 2009, Pages 551-556

  Chen, Z J ^a   Le, H B ^a   Zhang, Y K ^a   Qian, L Y ^a   Li, Wei Dong ^b  

^a First Hospital   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Immunohistochemistry; Microvessel density; Non small cell lung cancer; Thrombospondin 1

Indexed keywords

THROMBOSPONDIN 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; MICROVASCULATURE; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; LUNG TUMOR; METABOLISM; PATHOLOGY; VASCULARIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MICROVESSELS; THROMBOSPONDIN 1;

EID: 66649139008     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700232     Document Type: Article

References (14)

1. Ginberg MS, Grewal RK, Heelan RT: Lung Cancer. Radiol Clin North Am 2007; 45: 21-43.
2. Sessa C, Guibal A, Del Conte G, et al: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008; 5: 378-391.
3. Rofstad EK, Graff BA: Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts. J Invest Dermatol 2001; 117: 1042-1049.
4. Ren B, Yee KO, Lawler J, et al: Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765: 178-188.
5. Rami-Porta R, Crowley JJ, Goldstraw P: The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15: 4-9.
6. Yamaguchi M, Sugio K, Ondo K, et al: Reduced expression on thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 2002; 36: 143-150.
7. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86 353-364.
8. Vailhé B, Feige JJ: Thrombospondins as antiangiogenic therapeutic agents. Curr Pharm Des 2003; 9: 583-588.
9. Dudek AZ, Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005; 23: 193-200.
10. Lee CH, Wu CL, Shiau AL: Sytemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgenic expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005; 12: 175-184.
11. Simantov R, Febbraio M, Crombie R, et al: Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest 2001; 107: 45-52.
12. Hu J, Bianchi F, Ferguson M, et al: Gene expression signature for angiogenic and nonangiogenic non-small-ccell lung cancer. Oncogene 2005; 24: 1212-1219.
13. Guo N, Zabrenetzky VS, Chandrasekaran L, et al: Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Res 1998; 58: 3154-3162.
14. Gietema JA, Hoekstra R, de Vos FY, et al: A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 2006; 17: 1320-1327.